Literature DB >> 14730211

Biological significance of chromosomal imbalance aberrations in gastrointestinal stromal tumors.

Yi Chen1, Ching-Cherng Tzeng, Chiou-Ping Liou, Ming-Yu Chang, Chien-Feng Li, Ching-Nan Lin.   

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Current criteria for the diagnosis of malignant GISTs do not always reliably predict patient outcomes. In order to search for genetic markers with prognostic potential, chromosomal imbalance aberrations (CIAs) were analyzed in 28 subjects with GIST using comparative genomic hybridization and correlated with clinicopathological features. Except for a small rectal tumor, CIAs were identified in all GISTs, including 14 from the stomach, 11 from the small intestine, 1 from the esophagus, and 1 from the rectum. Losses were more common than gains. The median number of CIAs in high-risk GISTs was significantly higher than that in low-risk GISTs (5.60 +/- 2.59 vs. 3.38 +/- 2.55; p < 0.05), especially for losses (4.60 +/- 1.84 vs. 2.63 +/- 2.13; p < 0.01). Loss of 14q was the most common CIA in both low-risk and high-risk GISTs, and can be regarded as an early event of GIST development. Losses of 1p and 15q were also very common, often coexisting, and were slightly more frequent in high-risk GISTs than in low-risk GISTs. Other recurrent CIAs, including losses of 10q, 13q, 15q, 18q, and 22q and gains of 5p, 12q, 17q, and 20q were relatively less common in this series. Among these CIAs, losses of 13q, 10q (with minimal overlapping on q11-q22), and 22q were most likely the chromosomal loci potentially harboring the tumor suppressor gene(s) which may be related to early recurrence and/or metastasis during malignant transformation of GISTs. Copyright 2004 National Science Council, ROC and S. Karger AG, Basel

Entities:  

Mesh:

Year:  2004        PMID: 14730211     DOI: 10.1007/bf02256550

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  6 in total

1.  Mutational inactivation of mTORC1 repressor gene DEPDC5 in human gastrointestinal stromal tumors.

Authors:  Yuzhi Pang; Feifei Xie; Hui Cao; Chunmeng Wang; Meijun Zhu; Xiaoxiao Liu; Xiaojing Lu; Tao Huang; Yanying Shen; Ke Li; Xiaona Jia; Zhang Li; Xufen Zheng; Simin Wang; Yi He; Linhui Wang; Jonathan A Fletcher; Yuexiang Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-21       Impact factor: 11.205

Review 2.  Genetic aberrations of gastrointestinal stromal tumors.

Authors:  Jilong Yang; Xiaoling Du; Alexander J F Lazar; Raphael Pollock; Kelly Hunt; Kexin Chen; Xishan Hao; Jonathan Trent; Wei Zhang
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

3.  Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors.

Authors:  Martin G Belinsky; Lori Rink; Margaret von Mehren
Journal:  Front Oncol       Date:  2013-05-17       Impact factor: 6.244

4.  Prognostic significance of promyelocytic leukemia expression in gastrointestinal stromal tumor; integrated proteomic and transcriptomic analysis.

Authors:  Hiroshi Ichikawa; Akihiko Yoshida; Tatsuo Kanda; Shin-ichi Kosugi; Takashi Ishikawa; Takaaki Hanyu; Takahiro Taguchi; Marimu Sakumoto; Hitoshi Katai; Akira Kawai; Toshifumi Wakai; Tadashi Kondo
Journal:  Cancer Sci       Date:  2014-12-04       Impact factor: 6.716

5.  GSTT1 copy number gain and ZNF overexpression are predictors of poor response to imatinib in gastrointestinal stromal tumors.

Authors:  Eui Jin Lee; Guhyun Kang; Shin Woo Kang; Kee-Taek Jang; Jeeyun Lee; Joon Oh Park; Cheol Keun Park; Tae Sung Sohn; Sung Kim; Kyoung-Mee Kim
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

6.  Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors.

Authors:  Jean-Baptiste Bachet; Jean-François Emile
Journal:  Appl Clin Genet       Date:  2010-10-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.